National Institutes of Health logo
NIH Phase 1 Exploratory/Developmental Cooperative Agreement (UG3)

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)

Funds one bundled run from first-in-human through phase 2a for a dementia drug that works on something other than amyloid or tau.

Early dementia drug development loses years to the gaps between trials — each phase written, reviewed and funded separately while the compound waits. The National Institutes of Health funds the whole early stretch as one project here.

The applicant bundles independent protocols: a phase 1 trial together with phase 1b and phase 2a trials. They stay separate protocols, but they are planned, funded …

Bundled phase 1, phase 1b and phase 2a clinical trials of pharmacological candidates — small molecules or biologics — engaging non-amyloid and non-tau mechanisms to address cognitive or neuropsychiatric symptoms across the spectrum of Alzheimer's disease and related dementias, with prespecified go/no-go safety and tolerability milestones gating the advance between phases.

CycleiHow often this grant runs - e.g. annually, on a rolling basis, or a one-off call.Multiple per year
Next deadlineiThe next date applications are due. Rolling means you can apply any time.19 Nov 2026
Decision timeiTypical time from the deadline to the funder's decision.26 weeks
Project durationiHow long the funded work is expected to run.-
Award typeiThe form of funding - grant, equity, loan, tax credit, etc.Cooperative agreement
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.-
Funding pooliThe total budget available across all awards in this round.-

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see how they score you

Sign up free to see the timeline

Sign up free to see where teams trip up

Guides for this application

All guides →
National Institute on Aging logo
Open

NIA Alzheimer's Drug-Development Program

🇺🇸NIA · United States

Funds collaborative research alliances that accelerate Alzheimer's drug development in the United States.

BiotechMedtech+1
Nov'27
Centers for Disease Control and Prevention logo
Open

Emerging Infections Network - Research for Preventing, Detecting, and Managing Travel-associated Infectious Diseases

🇺🇸CDC · United States

Funds surveillance and research networks that detect, diagnose and track infectious diseases among international travelers.

Biotech
$1.8M – $6MNov'26
Army Medical Research and Development Command logo
Open

DOD Defense Health Agency (DHA) Research & Development FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research

🇺🇸MRDC / CDMRP · United States

Funds an unsolicited medical research idea across USAMRDC's whole portfolio, but only after a pre-proposal through eBRAP earns an invitation to submit in full.

Biotech
Sep'27
Army Medical Research and Development Command logo
Between cycles

DoW Military Burn, Technology/Therapeutic Development Award

🇺🇸MRDC / CDMRP · United States

Funds turning preclinical burn-care findings into an actual product — a device, a drug, or a clinical practice guideline.

BiotechMedtech
Army Medical Research and Development Command logo
Open

DoW Joint Warfighter Medical, Military Medical Research and Development Award

🇺🇸MRDC / CDMRP · United States

Funds a continuation phase for medical research that already holds earlier DOD or DOW funding, from preclinical work through clinical trials.

BiotechMedtech
Nov'26
NIH BRAIN Initiative logo
Open

Brain Behavior Quantification and Synchronization — Next Gen Sensor Technology Development

🇺🇸BRAIN Initiative · United States

Supports neural behavior-sensing technology development through translational cooperative projects.

NeurotechAI+2
Jun'27